Abstract:
Monoclonal antibodies which can bind to AIs proteins from Candida albicans are provided which can be useful in the treatment and protection against infection from yeast such as Candida albicans. The monoclonal antibodies of the invention are advantageous in that they are cross-reactive and can recognize multiple proteins from the AIs family. Suitable pharmaceutical compositions, vaccines and kits based on the monoclonal antibodies of the invention, as well as methods for their use, are also provided.
Abstract:
Monoclonal antibodies which can bind to AIs proteins from Candida albicans are provided which can be useful in the treatment and protection against infection from yeast such as Candida albicans. The monoclonal antibodies of the invention are advantageous in that they are cross-reactive and can recognize multiple proteins from the AIs family. Suitable pharmaceutical compositions, vaccines and kits based on the monoclonal antibodies of the invention, as well as methods for their use, are also provided.
Abstract:
Monoclonal antibodies which can bind to the SdrF protein of Staphylococcus epidermidis are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus epidermidis. The monoclonal antibodies of the invention are advantageous in that they can also recognize binding domains and subdomains of the S. epidermidis SdrF protein in addition to the protein itself. Suitable compositions and passive vaccines based on the monoclonal antibodies of the invention, as well as methods for their use, are also provided.
Abstract:
Monoclonal antibodies which can bind to the SdrF protein of Staphylococcus epidermidis are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus epidermidis . The monoclonal antibodies of the invention are advantageous in that they can also recognize binding domains and subdomains of the S. epidermidis SdrF protein in addition to the protein itself. Suitable compositions and passive vaccines based on the monoclonal antibodies of the invention, as well as methods for their use, are also provided.